Skip to content
Ryan Gill Lab

Ryan Gill Lab

Biotech Research

  • Home
  • Online antibody publications
  • Biotechnology engineer , why and how to become one ?
  • antibodies
  • Biotechnologically produced chitosan for nanoscale products. A legal analysis.
  • Biotechnology Governance 2.0: A Proposal for Minimum Standards in Biotechnology Corporate Governance.
  • Leaving the Bench and Finding Your Foundation.

Ryan Gill Lab

May 15, 2020May 15, 2020 by Pat Lynch

Our Lab:

Testing of antibodies
Testing Camel Monoclonale phage display antibodies on purity the kDa band is very sharp with Instant Blue
Elisa with Camel antibdies
Elisa analysis
Categories Default
Post navigation
What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.

Categories

  • Default
  • First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
  • The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.
  • What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.

Recent Posts

  • First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
  • The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.
  • What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.
  • Ryan Gill Lab

Tags

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.
© 2020 Ryan Gill Lab • Powered by GeneratePress